Deutsche Post Aktie WKN: 555200 / ISIN: DE0005552004

29,30EUR
-0,02EUR
-0,07%
22.06.2018
KAUFEN
VERKAUFEN

Analysen zu Deutsche Post AG

19.06.18Deutsche Post overweightMorgan Stanley
15.06.18Deutsche Post buySociété Générale Group S.A. (SG)
14.06.18Deutsche Post market-performBernstein Research
13.06.18Deutsche Post kaufenNorddeutsche Landesbank (Nord/LB)
13.06.18Deutsche Post UnderperformCredit Suisse Group
12.06.18Deutsche Post buyUBS AG
12.06.18Deutsche Post Sector PerformRBC Capital Markets
11.06.18Deutsche Post HaltenDZ BANK
11.06.18Deutsche Post HoldJefferies & Company Inc.
11.06.18Deutsche Post overweightBarclays Capital
11.06.18Deutsche Post buyCitigroup Corp.
11.06.18Deutsche Post HaltenIndependent Research GmbH
11.06.18Deutsche Post buyBaader Bank
11.06.18Deutsche Post buySociété Générale Group S.A. (SG)
11.06.18Deutsche Post ReduceKepler Cheuvreux
11.06.18Deutsche Post buyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
11.06.18Deutsche Post Conviction Buy ListGoldman Sachs Group Inc.
11.06.18Deutsche Post UnderperformCredit Suisse Group
11.06.18Deutsche Post buyDeutsche Bank AG
11.06.18Deutsche Post HoldHSBC
08.06.18Deutsche Post OutperformRBC Capital Markets
08.06.18Deutsche Post market-performBernstein Research
07.06.18Deutsche Post buyHSBC
06.06.18Deutsche Post UnderperformCredit Suisse Group
05.06.18Deutsche Post buyDeutsche Bank AG
28.05.18Deutsche Post HoldCommerzbank AG
22.05.18Deutsche Post buyWarburg Research
22.05.18Deutsche Post buyUBS AG
21.05.18Deutsche Post overweightBarclays Capital
17.05.18Deutsche Post buyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
15.05.18Deutsche Post OutperformRBC Capital Markets
15.05.18Deutsche Post market-performBernstein Research
14.05.18Deutsche Post kaufenNorddeutsche Landesbank (Nord/LB)
11.05.18Deutsche Post market-performBernstein Research
11.05.18Deutsche Post buyDeutsche Bank AG
10.05.18Deutsche Post buyDeutsche Bank AG
09.05.18Deutsche Post HoldS&P Capital IQ
09.05.18Deutsche Post HaltenIndependent Research GmbH
09.05.18Deutsche Post buyBaader Bank
09.05.18Deutsche Post buySociété Générale Group S.A. (SG)
Seite: 123456789...25

Kursziele Deutsche Post Aktie

+29,52%Abstand aktueller Kurs zum Ø Kursziel: +29,52%
Ø Kursziel: 37,95
Anzahl:
Buy: 12
Hold: 9
Sell: 2
25
30
35
40
45
50
55
BNP PARIBAS
50 €
JP Morgan Chase & Co.
40 €
S&P Capital IQ
38 €
Warburg Research
40 €
Commerzbank AG
41 €
HSBC
30,50 €
Deutsche Bank AG
37,60 €
Goldman Sachs Group Inc.
45 €
Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
38 €
Kepler Cheuvreux
28 €
Baader Bank
46 €
Independent Research GmbH
35 €
Citigroup Corp.
44 €
Barclays Capital
40 €
Jefferies & Company Inc.
34,50 €
RBC Capital Markets
33 €
UBS AG
37,20 €
Credit Suisse Group
30,11 €
Norddeutsche Landesbank (Nord/LB)
34 €
Bernstein Research
29 €
Société Générale Group S.A. (SG)
41 €
Morgan Stanley
43 €
Abstand aktueller Kurs zum Ø Kursziel: +29,52%
Ø Kursziel: 37,95
alle Deutsche Post Kursziele

Aktuelle News zu

19:47 UhrPositionen der deutschen und europäischen Verlegerverbände zum EU-Leistungsschutzrecht
19:45 UhrAthletic Brewing Company Launches State-Wide in Connecticut
19:30 UhrOne Drop Announces Blood Glucose Prediction and Automated Decision Support
19:01 UhrDiabeloop Insulin Delivery System May Significantly Improve Glycemic Control for People with Type 1 Diabetes
18:43 UhrThe Stars Group gibt Start des privaten Angebots von unbesicherten Schuldscheinen in Höhe von 750 Millionen USD bekannt
18:43 UhrFully Implantable, Continuous Glucose Monitoring Sensor Provided Accuracy for Six Months in Adolescents and Adults with Type 1 Diabetes
18:43 UhrDual-Hormone, Artificial Pancreas with Insulin and Pramlintide Significantly Improves Glucose Levels, Compared to Insulin-Only Artificial Pancreas
18:40 UhrOmnipod® Hybrid Closed-Loop Insulin Delivery System Significantly Improves Glycemic Control in Adults with Type 1 Diabetes
18:30 UhrVIA Opens Newest Park & Ride Facility in Stone Oak
18:30 UhrVieles spricht für Emerging Markets
18:27 UhrSpotify räumt beim Cannes Lions Festival of International Creativity ab
18:19 UhrHanergy stellt seine jüngsten Innovationen auf der Intersolar Europe aus
17:00 UhrImportant Questions To Ask Car Insurance Agents
16:57 UhrDer Tagesspiegel: Schäuble: Merkel bleibt bei einer Richtlinienentscheidung keine Wahl
16:30 UhrUnifor locals reach tentative agreements with Bombardier
16:30 UhrUnifor locals reach tentative agreements with Bombardier
16:23 UhrSpotify räumt beim Cannes Lions Festival of International Creativity ab
16:12 UhrTresiba® demonstrated significantly lower A1C and rates of hypoglycaemia versus insulin glargine U-300 in real-world evidence study
16:12 UhrTresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study
16:12 UhrTresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study
16:09 UhrOzempic® provided greater weight reductions for adults with a baseline BMI =25kg/m2 than those with lower baseline BMI <25kg/m2, in a SUSTAIN 7 post-hoc analysis
16:09 UhrOzempic® Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis
16:09 UhrOzempic® Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis
16:06 UhrOral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
16:06 UhrOral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial
16:06 UhrOral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial
16:03 UhrOne Third of Participants in a Workforce Study Reduce Risk for Diabetes after Employer Wellness Screening and Behavioral Counseling, Finds Quest Diagnostics Study
16:00 UhrGNation Shows That Gamers Care About Charity at E3 2018
16:00 UhrDr. John R. Burroughs of Springs Aesthetics Now Offering vFit PLUS Feminine Wellness Treatment Device
16:00 UhrReal-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
16:00 UhrFractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestine's Role in Type 2 Diabetes and NASH
16:00 UhrNew Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes
16:00 UhrJardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
16:00 UhrADT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ADT Inc. - ADT
16:00 UhrTresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study
16:00 UhrTresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study
15:47 UhrGaumard's Growing Family Takes Center Stage at AWHONN '18
15:00 UhrBay Shore Area Dealership Partners with Animal Rescue for Adoption Event
15:00 UhrStatement by the Prime Minister on the National Day of Remembrance for Victims of Terrorism
15:00 UhrStatement by the Prime Minister on the National Day of Remembrance for Victims of Terrorism
14:53 UhrEin Prosit auf die Bierbranche: Das sind die wahren WM-Sieger
14:05 UhrSignificant blood sugar improvement with Xultophy® 100/3.6 compared to insulin glargine U-100 when used as add-on to oral diabetes medications
14:05 UhrSignificant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications
14:00 UhrNew Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes
14:00 UhrTwo-year Data from ViaCyte's STEP ONE Clinical Trial Presented at ADA 2018
14:00 UhrInvestigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes
13:43 UhrCloud With Me: Converting Cloud Adoption Into an Accessible Solution for All
13:35 Uhr/R E P E A T -- Thousands of vapers from around the world descend on Toronto for Canada's Vape Expo (CVE)/
13:35 Uhr/R E P E A T -- Thousands of vapers from around the world descend on Toronto for Canada's Vape Expo (CVE)/
13:00 UhrSPA Selected as a 2018 Washington Post Top Workplace

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
Apple Inc.865985
Amazon906866
Scout24 AGA12DM8
TeslaA1CX3T
Volkswagen (VW) AG Vz.766403
Allianz840400
Alphabet C (ex Google)A14Y6H
Netflix Inc.552484
Facebook Inc.A1JWVX
Deutsche Telekom AG555750
Siemens Healthineers AGSHL100
BMW AG519000
MasterCard Inc.A0F602